iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
27 févr. 2020 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers – First patient enrolled in dose escalation portion of...
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
27 févr. 2020 01h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers – First patient enrolled in dose escalation portion of...
iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference
24 févr. 2020 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference Cambridge, MA and Gosselies, Belgium – February 24, 2020 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Present at SVB Leerink 9th Annual Global Healthcare Conference
18 févr. 2020 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at SVB Leerink 9th Annual Global Healthcare Conference Cambridge, MA and Gosselies, Belgium – February 18, 2020 – iTeos Therapeutics SA, a privately-held biotechnology...
iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region
30 janv. 2020 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region Funds will be used to progress iTeos’ two highly innovative clinical-stage oncology programs: a best-in class...
iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region
30 janv. 2020 01h00 HE
|
iTeos Therapeutics SA
Funds will be used to progress iTeos’ two highly innovative clinical-stage oncology programs: a best-in class A2A receptor antagonist and an ADCC-enabled anti-TIGIT antibody drug candidate ...
iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®
12 déc. 2019 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDAⓇ - Study will evaluate the safety and efficacy of the combination of...
iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®
12 déc. 2019 02h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDAⓇ - Study will evaluate the safety and efficacy of the combination of...
iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
26 nov. 2019 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference Cambridge, MA and Gosselies, Belgium – November 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...
iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer
13 août 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer Gosselies, Belgium and Cambridge, MA – 13 August, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...